SavedAdd your journal

Journals / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi / 2011 / Cilt: 20 - Sayı: 2

Kronik böbrek yetmezlikli hastalarda statinlerin pleiotropik etkilerinin değerlendirilmesi

Evaluation of pleiotropic effects of statins in chronic renal failure patients

Cengiz BAL
Sultan ÖZKURT
Mehmet SOYDAN
Özkan ALATAŞ
Garip ŞAHİN
Pages
150–155
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After LDL cholesterol level were reduced to under 100mg/day, we evaluated oxidized LDL, malondialdehyde (MDA), interleukin-6 (IL-6), high sensitive C reactive protein (hsCRP), fibrinogen, platelet count, sedimentation rate, nitric oxide (NO), Von Willebrand factor antigen (vWF ag), factor VIII (FVIII) and homocysteine.RESULTS: Significant reductions were obtained in total cholesterol, LDL-cholesterol (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVES: Atherosclerosis is seen more frequently in patients with chronic renal failure (CRF) due to the oxidative stress, chronic inflammation and endothelial dysfunction.
📊
Key Findings & Data:We aimed to investigate whether atorvastatin had pleiotropic effects in dialysis patients.MATERIAL and METHODS: 21 hyperlipidemic dialysis patients (12 on hemodialysis and 9 peritoneal dialysis) with LDL cholesterol levels over 130 mg/dl were included in this study.
💡
Conclusion & Impact:After LDL cholesterol level were reduced to under 100mg/day, we evaluated oxidized LDL, malondialdehyde (MDA), interleukin-6 (IL-6), high sensitive C reactive protein (hsCRP), fibrinogen, platelet count, sedimentation rate, nitric oxide (NO), Von Willebrand factor antigen (vWF ag), factor VIII (FVIII) and homocysteine.RESULTS: Significant reductions were obtained in total cholesterol, LDL-cholesterol (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVES: Atherosclerosis is seen more frequently in patients with chronic renal failure (CRF) due to the oxidative stress, chronic inflammation and endothelial dysfunction. Besides lowering total and low density lipoprotein (LDL) cholesterol levels, statins also lower the frequency of cardiovascular incidents in patients with chronic renal failure by their pleiotropic effects. We aimed to investigate whether atorvastatin had pleiotropic effects in dialysis patients.MATERIAL and METHODS: 21 hyperlipidemic dialysis patients (12 on hemodialysis and 9 peritoneal dialysis) with LDL cholesterol levels over 130 mg/dl were included in this study. Atorvastatin was titrated and given to patients for 6 months. After LDL cholesterol level were reduced to under 100mg/day, we evaluated oxidized LDL, malondialdehyde (MDA), interleukin-6 (IL-6), high sensitive C reactive protein (hsCRP), fibrinogen, platelet count, sedimentation rate, nitric oxide (NO), Von Willebrand factor antigen (vWF ag), factor VIII (FVIII) and homocysteine.RESULTS: Significant reductions were obtained in total cholesterol, LDL-cholesterol (p

Özet

AMAÇ: Kronik böbrek yetmezlikli hastalarda oksidatif stres, kronik inflamasyon ve endotel işlev bozukluğudan dolayı aterosklerozis daha sık görülür. Kronik böbrek yetmezlikli hastalarda statinler, toplam ve düşük dansiteli lipoprotein (LDL) kolesterolü düşürücü etkilerinin yanında pleiotropik etkileri ile kardiyovasküler olay sıklığını azaltırlar. Biz diyaliz hastalarında statinlerin pleiotropik etkilerinin olup olmadığını araştırmayı amaçladık.GEREÇ ve YÖNTEMLER: Çalışmaya LDL kolesterol düzeyi 130 mg/dl'den yüksek olan 21 diyaliz hastası (12 hemodiyaliz, 9 periton diyalizi) alındı. Atorvastatin titre edilerek 6 ay süreyle verildi. LDL kolesterol düzeyi 100 mg/dl altına indikten sonra oksidize LDL, malondialdehid (MDA), interleukin 6 (IL-6), yüksek duyarlıklı C reaktif protein (ydCRP), fibrinojen, platelet sayısı, sedimentasyon hızı, nitrik oksid (NO), Von Willebrand faktör antijeni (vWF ag), faktör VIII (FVIII) ve homosistein düzeylerini değerlendirdik.BULGULAR: Atorvastatin tedavisi ile total kolesterol, LDL kolesterol (p

🔖

Cite This Article

BAL, C., ÖZKURT, S., SOYDAN, M., ALATAŞ, Ö., ŞAHİN, G. (2022). Kronik böbrek yetmezlikli hastalarda statinlerin pleiotropik etkilerinin değerlendirilmesi. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, Cilt: 20 - Sayı: 2, 150–155. https://ajindex.com/articles/636426

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Annuk M, Zilmer M, Fellström B: Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int 2003
  2. 53 2. Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 1998
  3. 11(5): 239-245 3. Cases A, Vera M, Lopez Gomez JM: Cardiovascular risk in patient with chronic renal failure. Patients in renal replacement therapy. Nefrologia 2002
  4. 74 4. Stenvinkel P: Interactions between inflammation, oxidative stress and endothelial dysfunction in end-stage renal disease. J Ren Nutr 2003
  5. 13(2): 144-148 5. Oygar D: Hemodiyaliz tedavisi gören hastalarda iskemik kalp hastalığı, kalp yetmezliği ve perikarditin tedavisi. İçinde: Süleymanlar G, Erek E (ed). Diyaliz Tedavisi. Ankara. Güneş Kitabevi, 2004
  6. 358 6. Karadayı Ergin H, Alışır S, Aksoy Z: Kronik hemodiyaliz hastaları ile periton diyalizi hastalarının klasik koroner risk faktörleri ve homosistein düzeyleri açısından karşılaştırılması. İstanbul Tıp Fakültesi Mecmuası 2004
  7. 67(2): 1-5 7. Mastalerz-Migas A, Reksa D, Pokorski M, Steciwko A, Muszyńska A, Bunio A, Drobnik J, Pokorna-Kałwak D: Comparıson of a statin vs. hypolipemic diet on the oxidant status in hemodialyzed patients with chronic renal failure. J Physiol Pharmacol 2007
  8. 370 8. Perunicic-Pekovic GB, Pliesa SI, Rasic ZR, Stankovic SD, Ilic MN: Inflammatory markers, nutritional paremeters and polyunsaturated fatty acids in hemodialysis patients. Med Pregl 2007
  9. 47 9. Rubanyi GM: The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993
  10. 14 10. Önder MR, Barutcuoğlu B. İçinde: Önder MR, Barutcuoğlu B (ed). Endotel Dergisi 2005
  11. Ocak: 9-17 11. Borawski J, Naumnik B, Pawlak K, Mysliwiec M: Endothelial dysfunction marker von Willebrand factor antigen in hemodialysis patients: Associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 2001
  12. 1447 12. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C: Inflammation, endothelial dysfunction and platelet activation in patients with chronic kidney disease: The chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004
  13. 253 13. Sniderman AD, Solhpour A, Williams K, Sloand JA: Cardiovascular death in dialysis patients: Lessons we can learn from AURORA. Clin J Am Soc Nephrol 2010
  14. 340 14. Chan KE, Thadhani R, Lazarus JM, Hakim RM: Modeling